==> picture [163 x 54] intentionally omitted <==

FOR IMMEDIATE RELEASE

The Hon. Tony Abbott MHR Opens NuSep’s Head Office and Business Presentations

SYDNEY, AUSTRALIA – 24 August 2007 – NuSep Ltd (ASX: NSP) is pleased to announce that the Minister for Health and Ageing, The Hon. Tony Abbott MHR officially opened NuSep’s Head Office at Frenchs Forest on Thursday 23 August.

The event was attended by many shareholders and invited guests.

As part of this function, guests were updated on the business operations, attached are the 3 presentation;

1] Update on the NuSep business by Mr John Manusu CEO of NuSep.
2] Update on the Sperm Sorter project by Prof John Aitken, Director, ARC Centre of Excellence in Biotechnology and Development, University of Newcastle.
3] Update by Dr Brad Walsh on the Diagnostic Kits for Prostate Cancer and Diabetes being developed by Minomic International.

NuSep has recently made a strategic investment in Minomic International and now has 16.5% shareholding in Minomic.

About NuSep Ltd

NuSep is an Australian BioSeparations company based in Frenchs Forest, Sydney. NuSep manufactures and markets a range of products to BioSeparations customers located worldwide through distribution and sales centres located in Australia, the USA and Europe. NuSep is listed on the Australian Stock Exchange where its shares trade under the code “NSP”.

NuSep currently operates across three product groups, each addressing BioSeparations customers, utilising patented technology and leveraging the company’s global distribution network. The three product groups are as follows:

Electrophoresis gels – NuSep offers two pre-cast gel ranges: iGels, innovative gels including long-life gels and gels with solid well dividers; and NuBlu, high quality gels at an every day price together with associated consumables.
Gradiflow[®] Instruments – NuSep has developed two unique laboratory separation devices based on Gradiflow[®] technology. The first to be released in early 2008 is a proteomics instrument that can separate a biological sample into eight fractions. The second instrument will be applied to sperm separation required for fertility treatments such as IVF.

22 Rodborough Road � Frenchs Forest NSW 2086 � Australia � 61.2.8977.9000 � 61.2.8977.9099 fax NuSep Ltd ABN: 33 120 047 556

www.nusep.com

– 2 –

Development of this product is supported by the Australian Government’s Commercial Ready program.

Biological Products – NuSep supplies research grade reagents purified from human and animal plasma. The first product, human IgG was released in May 2007.

For more information about NuSep please visit the company’s website www.NuSep.com

Enquires/Additional information:

NuSep Ltd Prakash Patel Company Secretary (02) 8977 9000

# # # #

NuSep Business Outlook Mr John Manusu, CEO

Goal

To be the leading supplier to the BioSeparations market by providing products which lead the industry in terms of customer defined benefits

==> picture [411 x 242] intentionally omitted <==

Achievements since Floating

Establishment of direct global distribution
Launch of NuBlu Gels in the US
Expanded sales force
Launch of first biological reagent
Sperm Sorter enters clinical trials
Manufacturing and marketing rights for a prostate diagnostic kit
Short Form Prospectus

Growth Strategy

Seeking growth through acquisition of products and/or companies
Acquisition must fit with present business:

==> picture [294 x 40] intentionally omitted <==

Relevant to Life Science market

==> picture [294 x 39] intentionally omitted <==

Compliment NuSep technology and capabilities

==> picture [294 x 40] intentionally omitted <==

Compatible with distribution system

==> picture [294 x 40] intentionally omitted <==

Offer revenue growth

==> picture [294 x 40] intentionally omitted <==

Target monoclonal antibodies

==> picture [294 x 40] intentionally omitted <==

Why Monoclonal Antibodies?

Rapidly growing market – set to double in next 5 years
• Aggregate sales $US14b in 2005 (36.5% increase since 2004)
NuSep to target reagent market worth $US450m

==> picture [583 x 285] intentionally omitted <==

----- Start of picture text -----

mAb Market
Diagnostic
20%
Reagents NuSep Target
3%
Therapeutic
77%
----- End of picture text -----

What are Monoclonal Antibodies (mAbs)?

Antibodies that that can replicated endlessly
High purity and specificity
Able to recognise and bind to a specific antigen (eg. virus)
Used for:
Biomedical research
Disease diagnosis
Treatment of illness (eg. infections, cancer)

==> picture [162 x 192] intentionally omitted <==

Future Direction

First deal mAbs based product (in-license of prostate diagnostic kit)
Seeking additional opportunities
Targets assessed on following factors:
Profitability
Product portfolio and customer profile
Novel manufacture
Synergies with NuSep
Cashflow positive

Thank you

Cell Isolation Procedures for Human Spermatozoa

A joint venture with NuSep

==> picture [792 x 220] intentionally omitted <==

==> picture [392 x 52] intentionally omitted <==

==> picture [392 x 51] intentionally omitted <==

==> picture [159 x 60] intentionally omitted <==

==> picture [199 x 56] intentionally omitted <==

Cell Isolation Procedures for Human Spermatozoa

One in six Australian couples is affected by infertility

==> picture [576 x 299] intentionally omitted <==

----- Start of picture text -----

Ovulatory Failure
Idiopathic
Tubal Damage
Coital
Endometriosis
Mucus dysfunction
Male factor
Hull et al., 1985
----- End of picture text -----

At least one in twenty Australian males is infertile

==> picture [199 x 56] intentionally omitted <==

==> picture [95 x 37] intentionally omitted <==

==> picture [159 x 60] intentionally omitted <==

Assisted Reproductive Technology (ART) in Australia

41,000 ART cycles begin in Australia annually.

One in 25 Australian babies born this year will have been conceived through ART

The more of one generation you treat with ART the more the next generation will require ART

==> picture [199 x 56] intentionally omitted <==

==> picture [95 x 37] intentionally omitted <==

==> picture [159 x 60] intentionally omitted <==

Cell Isolation Procedures for Human Spermatozoa

One in 50 babies born through ART in Australia is stillborn or dies within a month of birth — twice the rate of babies conceived naturally.

Children conceived with ART also have about twice the risk of having a major birth defect or low birth weight than children conceived naturally

Nature’s barriers to fertilization by defective spermatozoa are circumvented

==> picture [199 x 56] intentionally omitted <==

==> picture [95 x 37] intentionally omitted <==

==> picture [159 x 60] intentionally omitted <==

DNA Damage in Sperm of Donors and Patients

==> picture [339 x 415] intentionally omitted <==

----- Start of picture text -----

55
Comet assay
50
45
40
35
30
25
20
15
10
5
Donor Patient
Median tail DNA
----- End of picture text -----

==> picture [226 x 308] intentionally omitted <==

==> picture [199 x 56] intentionally omitted <==

==> picture [95 x 37] intentionally omitted <==

==> picture [159 x 60] intentionally omitted <==